Technical Conference

• 

  

  
• 

  
• 

  

• Keynote Session

  【Keynote Session】

• IPJ-Kブロック

  

  Keynote Session [IPJ-K]

  Jun. 27 (Wed) 13:30-16:00 Bilingual (English/Japanese) Prospects of Japanese Pharmaceutical Industry and Keys to Further Success

  Perspective of the Japanese Pharmaceutical Market and Contributions from Pharmaceutical Companies	The Future of the Pharmaceutical Industry ―Teva's Global Strategy―	The Outsourcing Horizon: A New Value Model for the Future of Biopharmaceutical Development and Manufacturing
  Philippe Fauchet President, Representative Director, GlaxoSmithKline K.K.	Makoto Shimada President and CEO, Teva Pharma Japan Inc.	Harry Boot Chief Operating Officer, Lonza Life Science Ingredients, Lonza Ltd.

• Technical Sessions

  【Technical Sessions】
• 
  

  IPJ-1 Fast-changing Generic Industry ―Visions and Corporate Strategies― Jun. 27 (Wed) 9:30 - 12:30

  ・ President, Sawai Pharmaceutical Co., Ltd. / President, Japan Generic Medicine Association Hiroyuki Sawai ・ Teva Pharma Japan Inc. President and CEO, Makoto Shimada ・ Meiji Seika Pharma Co., Ltd. General Manager, Generics Marketing Dept., Yuji Umeki

  IPJ-6 Regulatory Trends and Implementations ―Genotoxic Impurity, Sterile Pharmaceuticals and CSV― Jun. 27 (Wed) 9:30 - 12:30

  ・ Eisai Group, Sunplanet Co., Ltd. Preclinical Safety Research Labs., Senior Director, Shigeki Sawada ・ Pharma Solutions Co., Ltd. Partner, Senior Consultant, Osamu Shirokizawa ・ SOAS Inc CEO, Takayuki Sugimoto

• IPJ-2 Front Line of High-value Added Formulation for LCM Jun. 28 (Thur) 9:30 - 12:30

  ・ Astellas Pharma Inc. Drug Delivery Pharmaceutical Research & Technology Labs., Senior Director, Shunsuke Watanabe ・ Ohara Pharmaceutical Co., Ltd. Drug Development Labs., Pharmaceutical Research Dept., Technical Adviser, Hiroshi Sakamoto ・ Dainippon Sumitomo Pharma Co., Ltd. Solid Dosage Form Research Group Ⅲ, Formulation Research & Development Labs., Technology Research & Development, Research Scientist, Hajime Tomita

  IPJ-7 Latest Global Trends of PIC/S and Efforts of Japanese Companies Bilingual (English/Japanese) Jun. 28 (Thur) 9:30 - 12:30

  ・ Bob Tribe Consulting/WHO Expert Committee on Specifications for Pharmaceutical Preparations Executive Consultant, Bob Tribe ・ Pharmaceuticals and Medical Devices Agency (PMDA) Office of GMP/QMS Inspection, Takashi Nagashima ・ Chugai Pharmaceutical Co., Ltd. Inspection and Audit Group, Quality Assurance Dept., Regulatory & Quality Management Unit, Leader, Nobuo Tateishi

• IPJ-3 Pharmaceutical Packaging in Pharmaceutical Companies and Medical Fronts Jun. 28 (Thur) 15:00 - 18:00

  ・ Chugai Pharmaceutical Co., Ltd. Production Engineering Dept., Pharmaceutical Technology Div., Packaging Development Group Manager, Masahiko Tanikawa ・ Astellas Pharma Inc. Product Promotion, Sales & Marketing, Associate Manager, Noriyuki Kinoshita ・ Nara Medical University Hospital Senior Healthcare Information Technologists, Pharmacy Unit, Kazuyuki Ikeda

  IPJ-8 QbD Applications: Beyond ICH Q8, 9, and 10 Concepts & Q11 Implementation Bilingual (English/Japanese) Jun. 28 (Thur) 15:00-18:00

  ・ Former Global Capital Director of AstraZeneca /  Former Chairman of International Board of ISPE Bruce Davis ・ Astellas Pharma Inc. Oral Formulation Technology, Pharmaceutical Research and Technology Labs., Masafumi Dohi ・ National Institute of Health Sciences (MHLW) Director, Div. of Drugs, Haruhiro Okuda

• IPJ-4 Latest Facilities and Manufacturing Technologies for Biotechnology-based Medicines Bilingual (English/Japanese) Jun. 29 (Fri) 9:30 - 12:30

  ・ Roche Diagnostics GmbH Pharma Biotech Penzberg, Vice President Tech. Dev. Bioprocessing, Josef Burg ・ IHI Plant Engineering Corp. Pharmaceutical &Fine Chemical Div., Senior Technical Adviser, Kazuo Sugaya ・ Asahi Glass Co., Ltd. Fellow, Hiromichi Kumagai

  IPJ-9 Containment Technologies and Evaluation Cases Bilingual (English/Japanese) Jun. 29 (Fri) 9:30 - 12:30

  ・ ILC Dover LP Pharmaceutical Products, Vice President Commercial Sales, Scott Patterson ・ Chiyoda Corp. Pharmaceutical Project Dept., Mikio Masuoka ・ TRAQuE Pte. Ltd. Director, Steve Slater

• IPJ-5 Vaccine Development and Manufacturing Technologies Worldwide Jun. 29 (Fri) 15:00 - 18:00

  ・ Osaka University Graduate School of Pharmaceutical Sciences, Professor, Shinsaku Nakagawa ・ Pfizer Japan Inc. Vaccine Market Development, Specialty Care, Director, Naoki Murata ・ GE Healthcare Japan Corp. Bio-Process Div., Technical Sales, Life Sciences, Technical Expert, Tokihide Fukuzawa

  IPJ-10 Update Status of Pharmaceutical Engineering Technologies and Applications Bilingual (English/Japanese) Jun. 29 (Fri) 15:00 - 18:00

  ・ Shionogi & Co., Ltd. CMC Development Labs., Head of Chemical Development Center, Norihiko Tanimoto ・ Towa Pharmaceutical Co., Ltd. General Manager of Yamagata Plant, Corporate Officer, Fumiaki Matsuura ・ GEA Pharma Systems, nv - Collette™ Sales Director, Wim Van der Goten

• Special Sessions

  【Special Sessions】

• IPJ-S1

  [Member Registration required]

  Interphex Japan Special Session1 [IPJ-S1]

  Jun. 28 (Thur) 13:00 - 14:30Bilingual (English/Japanese) Future Pharmaceutical R&D ―Key Factors for Competitiveness Improvement―

  For Japan-originated Innovation ―Lessons and Issues

  Kazuhiko Tanzawa Corporate Advisor, Daiichi Sankyo Co., Ltd

  The Strategy to Overcome Hurdles on the Pharmaceutical R&D

  Koji Kawakami Professor and Chairman, Dept. of Pharmacoepidemiology, School of Medicine and Public Health and Deputy Vice President (Research), Kyoto University

• IPJ-S2

  [Member Registration required]

  Interphex Japan Special Session2 [IPJ-S2]

  Jun 29 (Fri) 13:00 - 14:30Bilingual (English/Japanese) Leading Edge of Next-generation Pharmaceuticals ―Nucleic Acid Medicine & Epigenetic Drug Discovery―

  Nano Multifunctional Envelope-type Nano Device ―Medical Application of Nanotechnology―

  Hideyoshi Harashima Professor, Lab. for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University

  Development of Molecularly-targeted Epigenetic Drugs

  Takayoshi Suzuki Professor, Kyoto Prefectural University of Medicine

• IPJ-S3

  [Member Registration required]

  Interphex Japan Special Session3 [IPJ-S3]

  Jun. 28 (Thur) 15:30 - 17:00Bilingual (English/Japanese) Emergency Preparedness and Business Continuity of Pharmaceutical Facilities

  Learning Lessons from the March 11 Disaster ―Countermeasures Required for Pharmaceutical Plants

  Shinji Oshiguchi General Manager, Fukushima Plant, Ajinomoto Pharmaceuticals Co., Ltd.

  A Recent Approach to Seismic Performance Desired for Pharmaceutical Facilities ―Toward the Genuine Safety and a Sense of Security―

  Masato Ohata Manager, Advanced Structural Engineering, Engineering Dept., Takenaka Corp.

• PI-SI

  [Member Registration required]

  Pharma Japan Special Session1 [PI-S1]

  Jun. 28 (Thur) 10:30 - 12:00Bilingual (English/Japanese) Keys to Process Research and Approaches 1

  Strategies of Process Chemistry in Astellas Pharma Inc. ―Value Creation in New Technology―

  Minoru Okada Vice President, Process Chemistry Labs. Technology, Astellas Pharma Inc.

  Process Development of Drug Substances & Pharmaceutical Intermediates; Industrialization of High Potency API

  Yutaka Honda Associate General Manager, Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc.

• PI-S2

  [Member Registration required]

  Pharma Japan Special Session2 [PI-S2]

  Jun. 29 (Fri) 10:30 - 12:00Bilingual (English/Japanese) Keys to Process Research and Approaches 2

  Historic Changes and Prospects of Chiral Process Chemistry in Pharmaceutical Products Development

  Ryuzo Yoshioka Principal Research Scientist, Process Chemistry Research Labs., CMC Div., Former Mitsubishi Tanabe Pharma Corp.

  The Role and Practice of Process Research in Pharmaceutical Development

  Katsuya Tagami Executive Director, API Research, CMC Japan, Pharmaceutical Science & Technology Function Unit, Eisai Product Creation Systems, Eisai., Ltd.